October 25th 2023
Your daily dose of the clinical news you may have missed.
Weakness: Guidelines for a Cost-Effective Workup
December 1st 2007The differential diagnosis of generalized weakness is enormous; it includes disorders at all levels of the neur-axis. A variety of electrophysiological, pathological, radiographic, and other laboratory studies may be indicated depending on the specific diagnostic possibilities; costs can be controlled if such investigations are selected judiciously.
'Not your father's MRSA': What you need to know -- and do -- about community-associated MRSA
November 9th 2007The notoriously adaptable and increasingly common pathogen requires a new approach including routine I&D and culturing of infected tissues; the use of more-potent antibiotics, but only when needed; and a focus on hygiene in patients with recurrent infections.
Polypharmacy in Elderly Patients: Practical Tips to Avoid Adverse Effects and Interactions
November 1st 2007An 81-year-old woman with a history of moderate Alzheimer dementia, depression, coronary artery disease, hypertension, and type 2 diabetes mellitus was accompanied to the office by her son for a routine follow-up appointment.
Emerging Infections: What You Need to Know, Part 2
November 1st 2007Fear of bioterrorism persists because of new reports of biological warfare, including the most recent attack that involved a Russian spy who was poisoned with polonium-210. However, vaccination against potential biological weapons, such as anthrax and smallpox, is controversial because of associated adverse effects.
Secondary Syphilis and HIV Positivity
November 1st 2007Six months after testing positive for HIV in 10 bands, a 24-year-old homosexual man presented with a macular rash on his palms and soles. He first noticed the lesions 2 weeks earlier; they were not pruritic or painful. He also had a brighter, more inflamed rash in the groin and antecubital fossae that was presumed to be a yeast infection and was treated with fluconazole. He had no other symptoms.
FDA Approves First-in-Class Integrase Inhibitor for Treatment-Resistant HIV-1
October 15th 2007WHITEHOUSE STATION, N.J. -- The FDA has approved raltegravir (Isentress) as part of a combination regiment for treatment for multi-resistant HIV-1 infection in adults, according to an announcement from Merck.
IDSA: Rotavirus Infection, Not Just for Kids
October 11th 2007SAN DIEGO -- Rotavirus infection, once considered almost exclusively a pediatric diarrheal disease, affects adults as well, causing substantial morbidity and unnecessary use of procedures and antibiotics, according to results of a study reported here.
Does Stress Cause Disease? It Doesn't Help, Reviewers Say
October 10th 2007PITTSBURGH -- There is strong evidence suggesting -- but not proving -- the existence of a causal link between psychological stress and chronic conditions such as depression, cardiovascular disease, and HIV/AIDS, asserted researchers here.
IDSA: Neurologic and Psychiatric Problems Common Years after Perinatal HIV Infection
October 8th 2007SAN DIEGO -- Adolescents and teenagers with perinatally acquired HIV infection have high rates of neurologic, psychiatric, and cognitive problems that can confound attempts to treat them, investigators reported here.
No 'Slippery Slope' Found With Physician-Assisted Suicide
September 27th 2007SALT LAKE CITY -- Forecasts that physician-assisted suicide and euthanasia would be practiced disproportionately on vulnerable groups, such as the poor, the elderly, and women, did not prove accurate, according to researchers here.
With Hospitalists in Charge Patients Get Faster Discharge
September 24th 2007NEW YORK -- Inpatients cared for by full-time hospitalists were likely to be discharged almost a day sooner than those in the care of nonhospitalists, but there was no significant difference in readmission rates or mortality, researchers found.
ICAAC: Integrase Inhibitor Effective for HIV Patients with Multi-drug Resistant Disease
September 18th 2007CHICAGO -- The investigative integrase inhibitor raltegravir (Isentress) can suppress the viral load to undetectable levels in at least half of HIV patients with virus resistant to three drug classes, researchers said here.